DE69808440D1 - Verwendung von (+)mefloquine zur behandlung von malaria - Google Patents

Verwendung von (+)mefloquine zur behandlung von malaria

Info

Publication number
DE69808440D1
DE69808440D1 DE69808440T DE69808440T DE69808440D1 DE 69808440 D1 DE69808440 D1 DE 69808440D1 DE 69808440 T DE69808440 T DE 69808440T DE 69808440 T DE69808440 T DE 69808440T DE 69808440 D1 DE69808440 D1 DE 69808440D1
Authority
DE
Germany
Prior art keywords
quinolinemethanol
piperidinyl
trifluoromethyl
alpha
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69808440T
Other languages
English (en)
Other versions
DE69808440T2 (de
Inventor
Robin Shepherd
Allan Fletcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Application granted granted Critical
Publication of DE69808440D1 publication Critical patent/DE69808440D1/de
Publication of DE69808440T2 publication Critical patent/DE69808440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
DE69808440T 1997-03-07 1998-03-06 Verwendung von (+)mefloquine zur behandlung von malaria Expired - Fee Related DE69808440T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds
PCT/GB1998/000675 WO1998039003A1 (en) 1997-03-07 1998-03-06 Use of (+)mefloquine for the treatment of malaria

Publications (2)

Publication Number Publication Date
DE69808440D1 true DE69808440D1 (de) 2002-11-07
DE69808440T2 DE69808440T2 (de) 2003-07-10

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69808440T Expired - Fee Related DE69808440T2 (de) 1997-03-07 1998-03-06 Verwendung von (+)mefloquine zur behandlung von malaria

Country Status (11)

Country Link
US (1) US6664397B1 (de)
EP (1) EP0966285B1 (de)
JP (1) JP4380800B2 (de)
AT (1) ATE225177T1 (de)
AU (1) AU730818B2 (de)
DE (1) DE69808440T2 (de)
DK (1) DK0966285T3 (de)
ES (1) ES2185153T3 (de)
HK (1) HK1024631A1 (de)
PT (1) PT966285E (de)
WO (1) WO1998039003A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
US20070032480A1 (en) * 2005-06-14 2007-02-08 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
WO2009131657A1 (en) * 2008-04-21 2009-10-29 Duke University Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones
EP2411003A4 (de) * 2009-03-24 2012-10-17 Univ Singapore Verwendung von artemisininderivaten zur behandlung von asthma und chronisch obstruktiver lungenerkrankung (copd)
US8716265B2 (en) 2010-11-18 2014-05-06 Jenrin Discovery, Inc. 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (de) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Enantioselektives Syntheseverfahren von 4-Aminoalkoholchinolin-Derivaten sowie Nutzung
BR112015002697A8 (pt) * 2012-08-09 2018-01-16 Can Fite Biopharma Ltd uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
AU2018360285B2 (en) 2017-11-03 2023-08-24 Centre Hospitalier Universitaire D'amiens Novel aminopyridinemethanol compounds and their use
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
AU6506898A (en) 1998-09-22
ES2185153T3 (es) 2003-04-16
JP2001526637A (ja) 2001-12-18
WO1998039003A1 (en) 1998-09-11
EP0966285A1 (de) 1999-12-29
PT966285E (pt) 2002-12-31
ATE225177T1 (de) 2002-10-15
JP4380800B2 (ja) 2009-12-09
DK0966285T3 (da) 2002-10-28
HK1024631A1 (en) 2000-10-20
US6664397B1 (en) 2003-12-16
EP0966285B1 (de) 2002-10-02
DE69808440T2 (de) 2003-07-10
AU730818B2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
EA200400589A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
FI973163A (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
SE9701144D0 (sv) Novel compounds, their use and preparation
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK0998287T3 (da) Anvendelse af levobupivacain
ATE446748T1 (de) Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
DK1007055T3 (da) Anvendelse af amifostin
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
DE69805305T2 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
EP0302757A3 (de) Antiemetisch wirksame Serotonin-Depletoren
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
PT900082E (pt) Utilizacao de piridilpiperazina e pirimidilpiperazina para o fabrico de um medicamento para o tratamento de perturbacoes de toxicomania
DE60013876D1 (de) Nitroxyderivate von (r) und (s)-carnitin
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee